Brittany Marshburn, PA
Physician Assistant · Wilson, NCNPI 1417370644
Payments from drug & device makers
Across 90 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$232
- Novo Nordisk$172
- AstraZeneca$109
- Exact Sciences$95
- GSK$94
- Lilly USA, LLC$92
- plus $776 from 23 others
What the payments were for
- Food & beverage$1,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $232 |
| Novo Nordisk | 10 | $172 |
| AstraZeneca | 7 | $109 |
| Exact Sciences | 6 | $95 |
| GSK | 5 | $94 |
| Lilly USA, LLC | 6 | $92 |
| Amgen | 6 | $86 |
| Sumitomo Pharma America, Inc. | 4 | $79 |
| Pfizer | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Astellas Pharma US Inc | 2 | $40 |
| Abbott | 2 | $39 |
| Corcept Therapeutics | 2 | $36 |
| Boston Scientific | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Dexcom, Inc. | 2 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
| Zealand Pharma US, Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $23 |
| Ardelyx, Inc. | 1 | $22 |
| Merck | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
How this compares
$1,571 in reported general payments places this provider in the 75th percentile of 7,441 physician assistant providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 201 | $147,752 |
| MounjaroTirzepatide | 100 | $108,816 |
| OzempicSemaglutide | 91 | $106,684 |
| EliquisApixaban | 95 | $62,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $47,774 |
| RybelsusSemaglutide | 29 | $35,931 |
| TrulicityDulaglutide | 34 | $35,440 |
| GlyxambiEmpagliflozin/Linagliptin | 36 | $29,379 |
| MyrbetriqMirabegron | 43 | $21,980 |
| Repatha SyringeEvolocumab | 29 | $19,733 |
| FarxigaDapagliflozin Propanediol | 35 | $19,604 |
| JanuviaSitagliptin Phosphate | 12 | $17,935 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $17,090 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $16,401 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $14,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $31 | $184,745254 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $172 | $144,646131 claims |
| Lilly USA, LLCMounjaro, Trulicity | $92 | $144,256134 claims |
| PfizerEliquis | $59 | $62,99795 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $94 | $62,76190 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $21,98043 claims |
| AstraZenecaFarxiga | $109 | $19,60435 claims |
| MerckJanuvia | $19 | $17,93512 claims |
| AbbVieLinzess, Synthroid | $232 | $17,07252 claims |
| Johnson & JohnsonXarelto | $13 | $13,57411 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $32 | $6,52911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,441 physician assistant providers in North Carolina.
Other physician assistant in Wilson
- Philip ReasbeckWilson$180K
- Frank FerrittoWilson$90K
- James KovachWilson$59K
- Jo HughesGreensboro$814K
- Rachel HolzhauerCharlotte$739K
- Amber BlairCharlotte$551K
- Benjamin EpsteinDavidson$447K
- Rebecca KrausDavidson$425K
- Brooke JonesGoldsboro$259K
- Katherine SchultzHuntersville$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.